Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 18Breast Neoplasms 10Stomach Neoplasms 9Ovarian Neoplasms 8Prostatic Neoplasms 7Colorectal Neoplasms 6Cholangiocarcinoma 5Glioma 4Sarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Bile Duct Neoplasms 2Xanthogranuloma, Juvenile 1Thrombocytosis 1Sarcoma, Ewing 1

Interventions

pembrolizumab 25Nivolumab 20atezolizumab 8Magnetic Resonance Spectroscopy 7Ipilimumab 7Specimen Handling 5Paclitaxel 5Fluorodeoxyglucose F18 4Cyclophosphamide 4Carboplatin 4fludarabine 3durvalumab 3avelumab 3Interleukin-2 3Gemcitabine 3Docetaxel 3130-nm albumin-bound paclitaxel 3tislelizumab 2spartalizumab 2regorafenib 2epacadostat 2cabozantinib 2aldesleukin 2Taxes 2Pemetrexed 2FAPI-46 2Cisplatin 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × olaparib × Gastrointestinal × Clear all
NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡